Stockreport

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics, Inc.  (RNTX) 
PDF EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to [Read more]